Top

Published in:

01-06-2012 | Management of Macrovascular Disease in Diabetes (S Inzucchi and R Goldberg, Section Editors)

The Diagnosis and Management of Cerebrovascular Disease in Diabetes

Authors: Michael S. Phipps, Ania M. Jastreboff, Karen Furie, Walter N. Kernan

Published in: Current Diabetes Reports | Issue 3/2012

Abstract

Cerebrovascular disease is a leading cause of morbidity and mortality in diabetes. Compared with nondiabetic patients, diabetic patients have at least twice the risk for stroke, earlier onset of symptoms, and worse functional outcomes. Approximately 20 % of diabetic patients will die from stroke, making it one of the leading causes of death in this population. Effective strategies for primary and secondary prevention of stroke have been developed in research cohorts that included both diabetic and nondiabetic patients. Nevertheless, prevention in diabetes has some specific considerations. In this paper, we summarize evidence to guide the diagnosis and management of stroke in diabetic patients. We propose that diabetic stroke patients should have a robust risk assessment to target interventions, like other patients with cerebrovascular disease, but with special attention to glycemic control and lifestyle modification.

Heron M. Deaths: Leading causes for 2007. Natl Vital Stat Rep. 2011;59:1–95.PubMed

de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The verona diabetes study. Diabetes Care. 1999;22:756–61.PubMedCrossRef

Hankey GJ, Spiesser J, Hakimi Z, et al. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology. 2007;68:1583–7.PubMedCrossRef

Burchfiel CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22-year stroke incidence. The honolulu heart program. Stroke. 1994;25:951–7.PubMedCrossRef

Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The atherosclerosis risk in communities (aric) study investigators. Diabetes Care. 1999;22:1077–83.PubMedCrossRef

Kissela BM, Khoury J, Kleindorfer D, et al. Epidemiology of ischemic stroke in patients with diabetes: The greater cincinnati/northern kentucky stroke study. Diabetes Care. 2005;28:355–9.PubMedCrossRef

Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141–7.PubMedCrossRef

• Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: The northern manhattan study. Stroke. 2012;43:00–0. This population-based study examines not only the risk of ischemic stroke in diabetes, but also examines the effect of the duration of diabetes.CrossRef

Thacker EL, Psaty BM, McKnight B, et al. Fasting and post-glucose load measures of insulin resistance and risk of ischemic stroke in older adults. Stroke. 2011;42:3347–51.PubMedCrossRef

10.

Kernan WN, Inzucchi SE. Metabolic rehabilitation: Science gathers to support a new intervention to prevent stroke. Stroke. 2011;42:3333–5.PubMedCrossRef

11.

Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: The nurses’ health study. Diabetes Care. 2007;30:1730–5.PubMedCrossRef

12.

Feldmann E, Broderick JP, Kernan WN, et al. Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke. 2005;36:1881–5.PubMedCrossRef

13.

O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the interstroke study): A case–control study. Lancet. 2010;376:112–23.PubMedCrossRef

14.

Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–92.PubMedCrossRef

15.

Hillen T, Coshall C, Tilling K, et al. Cause of stroke recurrence is multifactorial: Patterns, risk factors, and outcomes of stroke recurrence in the south london stroke register. Stroke. 2003;34:1457–63.PubMedCrossRef

16.

Petty GW, Brown Jr RD, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: A population-based study in rochester, minnesota, 1975 through 1989. Neurology. 1998;50:208–16.PubMed

17.

Centers for disease control and prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the united states, 2011. Atlanta, ga: U.S. Department of health and human services, centers for disease control and prevention. 2011.

18.

Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged finnish population. Stroke. 1996;27:210–5.PubMedCrossRef

19.

Furie K, Inzucchi SE. Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Curr Neurol Neurosci Rep. 2008;8:12–9.PubMedCrossRef

20.

Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (sparcl) trial. Arch Neurol. 2011;68:1245–51.PubMedCrossRef

21.

Dhamoon MS, Tai W, Boden-Albala B, et al. Risk of myocardial infarction or vascular death after first ischemic stroke: The northern manhattan study. Stroke. 2007;38:1752–8.PubMedCrossRef

22.

Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.PubMedCrossRef

23.

Arboix A, Cendros V, Besa M, et al. Trends in risk factors, stroke subtypes and outcome. Nineteen-year data from the sagrat cor hospital of barcelona stroke registry. Cerebrovasc Dis. 2008;26:509–16.PubMedCrossRef

24.

Auriel E, Gur AY, Uralev O, et al. Characteristics of first ever ischemic stroke in the very elderly: Profile of vascular risk factors and clinical outcome. Clin Neurol Neurosurg. 2011;113:654–7.PubMedCrossRef

25.

Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the american heart association. Circulation. 1999;100:1134–46.PubMed

26.

Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: The atherosclerosis risk in communities study. Heart. 2012;98:133–8.PubMedCrossRef

27.

Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: Epidemiology and possible mechanisms. Diabetes Care. 2007;30:3131–40.PubMedCrossRef

28.

Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: Focus on stroke. Endocr Metab Immune Disord Drug Targets 2011.

29.

Turan TN, Makki AA, Tsappidi S, et al. Risk factors associated with severity and location of intracranial arterial stenosis. Stroke. 2010;41:1636–40.PubMedCrossRef

30.

Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422–6.PubMedCrossRef

31.

Megherbi SE, Milan C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: Data from the european biomed stroke project. Stroke. 2003;34:688–94.PubMedCrossRef

32.

Koennecke HC, Belz W, Berfelde D, et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology. 2011;77:965–72.PubMedCrossRef

33.

Protopsaltis J, Kokkoris S, Korantzopoulos P, et al. Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke. Atherosclerosis. 2009;203:228–35.PubMedCrossRef

34.

• Reeves MJ, Vaidya RS, Fonarow GC, et al. Quality of care and outcomes in patients with diabetes hospitalized with ischemic stroke: Findings from get with the guidelines-stroke. Stroke. 2010;41:e409–417. This study is a great examination of the quality of care provided to patients with diabetes and ischemic stroke.PubMedCrossRef

35.

Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: A report from the american heart association. Circulation. 2012;125:e2–e220.PubMedCrossRef

36.

Tetri S, Juvela S, Saloheimo P, et al. Hypertension and diabetes as predictors of early death after spontaneous intracerebral hemorrhage. J Neurosurg. 2009;110:411–7.PubMedCrossRef

37.

Arboix A, Massons J, Garcia-Eroles L, et al. Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage. Diabetes Care. 2000;23:1527–32.PubMedCrossRef

38.

Mizrahi EH, Fleissig Y, Arad M, et al. Functional outcome of ischemic stroke: A comparative study of diabetic and non-diabetic patients. Disabil Rehabil. 2007;29:1091–5.PubMedCrossRef

39.

•• Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227–76. AHA/American Stroke Association guidelines for prevention of recurrent stroke, with a review of the evidence.PubMedCrossRef

40.

Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the ninds rt-pa stroke trial. Neurology. 2002;59:669–74.PubMed

41.

Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke. 2001;32:2426–32.PubMedCrossRef

42.

Hatzitolios AI, Didangelos TP, Zantidis AT, et al. Diabetes mellitus and cerebrovascular disease: Which are the actual data? J Diabetes Complications. 2009;23:283–96.PubMedCrossRef

43.

Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ. 1997;314:1303–6.PubMedCrossRef

44.

Williams LS, Rotich J, Qi R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002;59:67–71.PubMed

45.

Ahmed N, Davalos A, Eriksson N, et al. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: Results from the safe implementation of treatments in stroke international stroke thrombolysis register (sits-istr). Arch Neurol. 2010;67:1123–30.PubMedCrossRef

46.

Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003;34:2208–14.PubMedCrossRef

47.

Jorgensen HS, Reith J, Nakayama H, et al. Potentially reversible factors during the very acute phase of stroke and their impact on the prognosis: Is there a large therapeutic potential to be explored? Cerebrovasc Dis. 2001;11:207–11.PubMedCrossRef

48.

Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Ann Neurol. 2002;52:20–8.PubMedCrossRef

49.

Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ecass-ii trial. Stroke. 2008;39:2749–55.PubMedCrossRef

50.

Hyvarinen M, Tuomilehto J, Mahonen M, et al. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. Stroke. 2009;40:1633–7.PubMedCrossRef

51.

Labovitz DL, Boden-Albala B, Hauser WA, Sacco RL. Lacunar infarct or deep intracerebral hemorrhage: Who gets which? The northern manhattan study. Neurology. 2007;68:606–8.PubMedCrossRef

52.

Arauz A, Murillo L, Cantu C, et al. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: Risk factors, recurrence, and outcome in 175 consecutive cases. Stroke. 2003;34:2453–8.PubMedCrossRef

53.

Jackson CA, Hutchison A, Dennis MS, et al. Differing risk factor profiles of ischemic stroke subtypes: Evidence for a distinct lacunar arteriopathy? Stroke. 2010;41:624–9.PubMedCrossRef

54.

Mast H, Thompson JL, Lee SH, et al. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke. 1995;26:30–3.PubMedCrossRef

55.

Adams Jr HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115:e478–534.PubMedCrossRef

56.

Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation. 2011;124:477–86.PubMedCrossRef

57.

•• Morgenstern LB, Hemphill 3rd JC, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29. AHA/American Stroke Associations guidelines for management of spontaneous ICH, with review of the evidence.PubMedCrossRef

58.

Stöllberger C, Exner I, Finsterer J, et al. Stroke in diabetic and non-diabetic patients: Course and prognostic value of admission serum glucose. Ann Med. 2005;37:357–64.PubMedCrossRef

59.

Mishra NK, Ahmed N, Davalos A, et al. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology. 2011;77:1866–72.PubMedCrossRef

60.

Mishra NK, Davis SM, Kaste M, Lees KR. Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (Vista). Diabetes Care. 2010;33:2531–7.PubMedCrossRef

61.

Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe implementation of thrombolysis in stroke-monitoring study (sits-most). Stroke. 2008;39:3316–22.PubMedCrossRef

62.

Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34–9.PubMedCrossRef

63.

Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The mast-e study. Mast-e group. Stroke. 1999;30:1326–32.PubMedCrossRef

64.

Celik Y, Utku U, Asil T, Balci K. Factors affecting haemorrhagic transformation in middle cerebral artery infarctions. J Clin Neurosci. 2004;11:656–8.PubMedCrossRef

65.

Bruno A, Biller J, Adams Jr HP. et al.: Acute blood glucose level and outcome from ischemic stroke. Trial of org 10172 in acute stroke treatment (toast) investigators. Neurology. 1999;52:280–4.PubMed

66.

Fuentes B, Martinez-Sanchez P, Alonso de Lecinana M, et al. Diabetes and previous stroke: Hazards for intravenous thrombolysis? Eur J Neurol 2011

67.

Poppe AY, Majumdar SR, Jeerakathil T, et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care. 2009;32:617–22.PubMedCrossRef

68.

Tandberg Askevold E, Naess H, Thomassen L. Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16:21–4.PubMedCrossRef

69.

Zangerle A, Kiechl S, Spiegel M, et al. Recanalization after thrombolysis in stroke patients: Predictors and prognostic implications. Neurology. 2007;68:39–44.PubMedCrossRef

70.

Kimura K, Sakamoto Y, Iguchi Y, et al. Admission hyperglycemia and serial infarct volume after t-pa therapy in patients with and without early recanalization. J Neurol Sci. 2011;307:55–9.PubMedCrossRef

71.

McCormick M, Hadley D, McLean JR, et al. Randomized, controlled trial of insulin for acute poststroke hyperglycemia. Ann Neurol. 2010;67:570–8.PubMedCrossRef

72.

Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (this) a randomized pilot trial. Stroke. 2008;39:384–9.PubMedCrossRef

73.

• Johnston KC, Hall CE, Kissela BM, et al. Glucose regulation in acute stroke patients (grasp) trial: A randomized pilot trial. Stroke. 2009;40:3804–9. A trial examining the safety of insulin infusion therapy in acute ischemic stroke.PubMedCrossRef

74.

Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008, 358:2545–59.

75.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358:2560–72.

76.

• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine. 2009;360:129–39. Important Veterans Administration study finding no improvement of intensive glycemic control versus standard control.PubMedCrossRef

77.

Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef

78.

Bellolio MF, Gilmore RM, Stead LG. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2011;9:CD005346.PubMed

79.

•• Standards of medical care in diabetes—2012. Diabetes Care 2012;35:S11–63. ADA guidelines for management of diabetes, with a review of the evidence.

80.

Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31.PubMedCrossRef

81.

Guidelines for improving the care of the older person with diabetes mellitus. Journal of the American Geriatrics Society 2003;51:S265–80.

82.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (ukpds 34). The Lancet 1998;352:854–65.

83.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRef

84.

Colwell JA, Association AD. Aspirin therapy in diabetes. Diabetes Care. 2004;27 Suppl 1:S72–73.PubMed

85.

Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRef

86.

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). The Lancet 1996;348:1329–39.

87.

Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–7.PubMedCrossRef

88.

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef

89.

• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. A study from the ACCORD trial examining the effect of BP control on cardiovascular outcomes in patients with type 2 diabetes.PubMedCrossRef

90.

Anushka P. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. The Lancet. 2007;370:829–40.CrossRef

91.

MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. The Lancet 2003;361:2005–16.

92.

Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Circulation. 2004;110:227–39.PubMedCrossRef

93.

Dorigo W, Pulli R, Pratesi G, et al. Early and long-term results of carotid endarterectomy in diabetic patients. J Vasc Surg. 2011;53:44–52.PubMedCrossRef

94.

Salenius JP, Harju E, Riekkinen H. Early cerebral complications in carotid endarterectomy: Risk factors. J Cardiovasc Surg (Torino). 1990;31:162–7.

95.

Tu JV, Wang H, Bowyer B, et al. Risk factors for death or stroke after carotid endarterectomy: Observations from the Ontario carotid endarterectomy registry. Stroke. 2003;34:2568–73.PubMedCrossRef

96.

Debing E, Aerden D, Van den Brande P. Diabetes mellitus is a predictor for early adverse outcome after carotid endarterectomy. Vasc Endovascular Surg. 2011;45:28–32.PubMedCrossRef

97.

Ballotta E, Da Giau G, Renon L. Is diabetes mellitus a risk factor for carotid endarterectomy? A prospective study. Surgery. 2001;129:146–52.PubMedCrossRef

98.

Pistolese GR, Appolloni A, Ronchey S, Martelli E. Carotid endarterectomy in diabetic patients. J Vasc Surg. 2001;33:148–54.PubMedCrossRef

99.

Rockman CB, Saltzberg SS, Maldonado TS, et al. The safety of carotid endarterectomy in diabetic patients: Clinical predictors of adverse outcome. J Vasc Surg. 2005;42:878–83.PubMedCrossRef

100.

Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look ahead trial. Arch Intern Med. 2010;170:1566–75.PubMedCrossRef

Title: The Diagnosis and Management of Cerebrovascular Disease in Diabetes
Authors: Michael S. Phipps
Ania M. Jastreboff
Karen Furie
Walter N. Kernan
Publication date: 01-06-2012
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 3/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0271-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Diagnosis and Management of Cerebrovascular Disease in Diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Is It Time to Screen for the Haptoglobin Genotype to Assess the Cardiovascular Risk Profile and Vitamin E Therapy Responsiveness in Patients with Diabetes?

Type 1 Diabetes Mellitus in India

Update on Diabetic Cardiomyopathy: Inches Forward, Miles to Go

Diagnosis of Coronary Artery Disease in Persons with Diabetes Mellitus

Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials

Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page